DaVita HealthCare Partners Inc. (NYSE:DVA) – Analysts at KeyCorp lowered their FY2018 earnings per share estimates for shares of DaVita HealthCare Partners in a note issued to investors on Tuesday. KeyCorp analyst J. Gurda now forecasts that the company will post earnings of $3.58 per share for the year, down from their prior forecast of $3.90. KeyCorp has a “Hold” rating on the stock.

DaVita HealthCare Partners (NYSE:DVA) last released its quarterly earnings data on Tuesday, August 1st. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.02. DaVita HealthCare Partners had a net margin of 8.68% and a return on equity of 14.02%. The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter last year, the firm earned $1.01 EPS. DaVita HealthCare Partners’s quarterly revenue was up 4.3% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: This article was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/10/12/keycorp-comments-on-davita-healthcare-partners-inc-s-fy2018-earnings-dva-2.html.

A number of other research firms also recently weighed in on DVA. Jefferies Group LLC downgraded shares of DaVita HealthCare Partners from a “buy” rating to a “hold” rating and increased their target price for the company from $64.89 to $70.00 in a research report on Monday, June 26th. Zacks Investment Research downgraded shares of DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. BidaskClub downgraded shares of DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research report on Saturday, July 8th. J P Morgan Chase & Co downgraded shares of DaVita HealthCare Partners from a “neutral” rating to an “underweight” rating in a research report on Monday. Finally, TheStreet downgraded shares of DaVita HealthCare Partners from a “b” rating to a “c+” rating in a research report on Wednesday, August 2nd. Four research analysts have rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company. DaVita HealthCare Partners has a consensus rating of “Hold” and a consensus target price of $66.50.

DaVita HealthCare Partners (NYSE DVA) traded down 0.71% on Thursday, reaching $54.17. 1,133,054 shares of the company traded hands. The stock has a market capitalization of $10.36 billion, a PE ratio of 8.25 and a beta of 0.90. The firm has a 50 day moving average of $58.41 and a 200-day moving average of $63.07. DaVita HealthCare Partners has a one year low of $53.58 and a one year high of $70.16.

Several hedge funds have recently made changes to their positions in DVA. BlackRock Inc. grew its position in shares of DaVita HealthCare Partners by 2,315.8% during the 1st quarter. BlackRock Inc. now owns 12,892,477 shares of the company’s stock worth $876,303,000 after buying an additional 12,358,806 shares during the period. Park West Asset Management LLC grew its position in shares of DaVita HealthCare Partners by 88.8% during the 1st quarter. Park West Asset Management LLC now owns 1,856,516 shares of the company’s stock worth $126,187,000 after buying an additional 873,064 shares during the period. Tudor Investment Corp ET AL acquired a new stake in shares of DaVita HealthCare Partners during the 1st quarter worth approximately $31,376,000. PGGM Investments acquired a new stake in shares of DaVita HealthCare Partners during the 2nd quarter worth approximately $28,598,000. Finally, Highbridge Capital Management LLC grew its position in shares of DaVita HealthCare Partners by 45,626.9% during the 1st quarter. Highbridge Capital Management LLC now owns 364,215 shares of the company’s stock worth $24,756,000 after buying an additional 365,015 shares during the period. 83.27% of the stock is owned by institutional investors.

DaVita HealthCare Partners announced that its Board of Directors has approved a stock repurchase program on Tuesday, October 10th that authorizes the company to buyback $1.50 billion in shares. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Earnings History and Estimates for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.